CD34+ cells offer valuable insights into hematopoiesis, hematological disorders, and regenerative medicine. They have potential in cancer therapies, autoimmune diseases, and genetic disorders. Isolating CD34+ cells from Cord Blood Mononuclear Cells (MNC) is crucial for research in hematopoietic stem cell biology and therapeutic advancements. MARS® Platform ensures the enrichment of CD34+ cells, enhancing purity, viability, and yield for advancing innovations in personalized treatments, including cellular therapies.
